RECOVERY trial results demonstrate baricitinib reduces deaths in hospitalised COVID-19 patients

• BenevolentAI first identified baricitinib as a potential COVID-19 treatment in January 2020 and published its hypothesis in The Lancet and in The Lancet Infectious Diseases

• The RECOVERY data adds to the growing body of evidence from nine clinical trials across 12,000 patients in which the use of baricitinib (or another JAK inhibitor) was found to reduce deaths in hospitalised COVID-19 patients by approximately one-fifth (rate ratio 0.80, 95% CI 0.71 to 0.89; p<0.001)

London, 4 March 2022, The University of Oxford team running the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial, which recruited over 4,000 patients, have announced that treatment with baricitinib reduces deaths in patients hospitalised with COVID-19 by 13% (rate ratio 0.87, 95% CI 0.77 to 0.98; p=0.026). The benefit was greatest in those seriously ill and additive to that of dexamethasone and tocilizumab, two other anti-inflammatory treatments which have previously been shown to reduce the risk of death in these patients.

Dr Anne Phelan, Chief Scientific Officer at BenevolentAI, commented: “This story started with our novel AI-derived hypothesis, which quickly led to unprecedented global scientific collaboration from public, private and non-profit organisations around the world. Each has played their part in bringing this game-changing discovery to patients. Today that story comes full circle, with another life-saving COVID-19 treatment added to the clinical armamentarium, further validating our hypothesis. The significance of this spans beyond COVID-19: it demonstrates that our technology can fundamentally transform the way we understand disease biology and help uncover new treatment approaches for thousands of diseases.” 

RECOVERY is one of nine clinical trials of baricitinib and similar drugs (known as JAK inhibitors) for the treatment of COVID-19. Across these nine trials, which involve around 12,000 patients, the use of baricitinib (or another JAK inhibitor) was found to reduce deaths in hospitalised COVID-19 patients by approximately one-fifth. In the RECOVERY trial, baricitinib also increased the chances of patients being discharged alive within 28 days and reduced the risk of their condition worsening.

BenevolentAI first identified baricitinib as a potential COVID-19 treatment in January 2020, and published this research in The Lancet and in The Lancet Infectious Diseases. The company’s scientists used its AI platform and biomedical Knowledge Graph to search for already approved drugs that could both inhibit viral entry into cells, and deliver an anti-inflammatory effect to reduce the body’s extreme immune response known as the cytokine storm. Baricitinib, an oral JAK inhibitor, owned by Eli Lilly and approved for rheumatoid arthritis, was identified as the most promising treatment from a list of thousands of potential drugs. During a 48 hour accelerated search process, the team uncovered baricitinib’s previously unknown anti-viral properties, in addition to its already known anti-inflammatory effects. 

BenevolentAI’s research sparked global trials of baricitinib to treat COVID-19, such as the NIAID ACTT-II. Eli Lilly’s placebo-controlled trial, COV-BARRIER, showed baricitinib reduced deaths in hospitalised COVID-19 patients by 38%. Baricitinib has been strongly recommended by the World Health Organisation (WHO) at its highest evidence level in the BMJ Living Review. It has been authorised for emergency use as a solo treatment for hospitalised patients by the FDA, or in combination with remdesivir.

About BenevolentAI

BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track-record of scientifically validated discoveries. The BenevolentAI PlatformTM powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

More Posts

You Might Also Like

Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022